**Peer Review Journal ** DOI on demand of Author (Charges Apply) ** Fast Review and Publicaton Process ** Free E-Certificate to Each Author

Current Issues
     2026:7/1

International Journal of Medical and All Body Health Research

ISSN: (Print) | 2582-8940 (Online) | Impact Factor: 6.89 | Open Access

RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF)

Abstract

A novel, simple, accurate, precise, sensitive and specific analytical RP-HPLC method was developed and validated for the quantitative estimation of Ruxolitinib in bulk drugs and pharmaceutical dosage form. Chromatographic separation was achieved on an Symmetry ODS C18 (4.6×250mm, 5µm) analytical column using mobile phase composition of methanol and Phosphate Buffer in ratio of (35: 65 v/v) that was set at a flow rate of 1.0μl/min with detection of 235 nm. The retention time of Ruxolitinib was found to be 3.006min. The drug was analyzed by following the guidelines of International conference on Harmonization (ICH). This drug showing linearity in the concentration range of 6-14µg/ml and the correlation coefficient showing R2 = 0.9996. The % Recoveries showing within the limits. The presentation of the method was validated according to the present ICH guidelines for accuracy, precision and robustness, Linearity, limit of quantification, limit of detection linearity. 

How to Cite This Article

J Prathusha, Utti Ramakrishna, Kavali Poojitha, Kota Amulya, N Radhikareddy (2024).

RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form

. International Journal of Medical and All Body Health Research (IJMABHR), 5(2), 15-21.

Share This Article: